These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

768 related articles for article (PubMed ID: 29447848)

  • 1. Effects of tablet formulation and subsequent film coating on the supersaturated dissolution behavior of amorphous solid dispersions.
    Sakai T; Hirai D; Kimura SI; Iwao Y; Itai S
    Int J Pharm; 2018 Apr; 540(1-2):171-177. PubMed ID: 29447848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ternary Amorphous Solid Dispersions Containing a High-Viscosity Polymer and Mesoporous Silica Enhance Dissolution Performance†.
    Hanada M; Jermain SV; Thompson SA; Furuta H; Fukuda M; Williams RO
    Mol Pharm; 2021 Jan; 18(1):198-213. PubMed ID: 33291881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulation of fast disintegrating tablets of ternary solid dispersions consisting of TPGS 1000 and HPMC 2910 or PVPVA 64 to improve the dissolution of the anti-HIV drug UC 781.
    Goddeeris C; Willems T; Van den Mooter G
    Eur J Pharm Sci; 2008 Aug; 34(4-5):293-302. PubMed ID: 18602800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissolution and precipitation behavior of amorphous solid dispersions.
    Alonzo DE; Gao Y; Zhou D; Mo H; Zhang GGZ; Taylor LS
    J Pharm Sci; 2011 Aug; 100(8):3316-3331. PubMed ID: 21607951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into the Dissolution Mechanism of Ritonavir-Copovidone Amorphous Solid Dispersions: Importance of Congruent Release for Enhanced Performance.
    Indulkar AS; Lou X; Zhang GGZ; Taylor LS
    Mol Pharm; 2019 Mar; 16(3):1327-1339. PubMed ID: 30669846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Theoretical evaluation of supersaturation of amorphous solid dispersion formulations with different drug/polymer combinations using mathematical modeling.
    Hirai D; Tsunematsu H; Kimura SI; Itai S; Fukami T; Iwao Y
    Int J Pharm; 2022 Sep; 625():122110. PubMed ID: 35970282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wetting Kinetics: an Alternative Approach Towards Understanding the Enhanced Dissolution Rate for Amorphous Solid Dispersion of a Poorly Soluble Drug.
    Verma S; Rudraraju VS
    AAPS PharmSciTech; 2015 Oct; 16(5):1079-90. PubMed ID: 25672820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mathematical model to analyze the dissolution behavior of metastable crystals or amorphous drug accompanied with a solid-liquid interface reaction.
    Hirai D; Iwao Y; Kimura SI; Noguchi S; Itai S
    Int J Pharm; 2017 Apr; 522(1-2):58-65. PubMed ID: 28235625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation performance and processability window for manufacturing a dual-polymer amorphous solid dispersion via hot-melt extrusion and strand pelletization.
    Hörmann TR; Jäger N; Funke A; Mürb RK; Khinast JG; Paudel A
    Int J Pharm; 2018 Dec; 553(1-2):408-421. PubMed ID: 30326284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of hydroxypropyl methylcellulose as a protective agent against magnesium stearate induced crystallization of amorphous itraconazole.
    Démuth B; Galata DL; Balogh A; Szabó E; Nagy B; Farkas A; Hirsch E; Pataki H; Vigh T; Mensch J; Verreck G; Nagy ZK; Marosi G
    Eur J Pharm Sci; 2018 Aug; 121():301-308. PubMed ID: 29902510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of the potential of poly(2-ethyl-2-oxazoline) as carrier in the formulation of amorphous solid dispersions of poorly soluble drugs.
    Boel E; Smeets A; Vergaelen M; De la Rosa VR; Hoogenboom R; Van den Mooter G
    Eur J Pharm Biopharm; 2019 Nov; 144():79-90. PubMed ID: 31499162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physicochemical properties of tadalafil solid dispersions - Impact of polymer on the apparent solubility and dissolution rate of tadalafil.
    Wlodarski K; Sawicki W; Haber K; Knapik J; Wojnarowska Z; Paluch M; Lepek P; Hawelek L; Tajber L
    Eur J Pharm Biopharm; 2015 Aug; 94():106-15. PubMed ID: 25998701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A New Extrudable Form of Hypromellose: AFFINISOL™ HPMC HME.
    Huang S; O'Donnell KP; Keen JM; Rickard MA; McGinity JW; Williams RO
    AAPS PharmSciTech; 2016 Feb; 17(1):106-19. PubMed ID: 26335416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced kinetic solubility profiles of indomethacin amorphous solid dispersions in poly(2-hydroxyethyl methacrylate) hydrogels.
    Sun DD; Ju TC; Lee PI
    Eur J Pharm Biopharm; 2012 May; 81(1):149-58. PubMed ID: 22233548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism-based selection of stabilization strategy for amorphous formulations: Insights into crystallization pathways.
    Edueng K; Mahlin D; Larsson P; Bergström CAS
    J Control Release; 2017 Jun; 256():193-202. PubMed ID: 28412224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of ternary solid dispersions of itraconazole, PEG 6000, and HPMC 2910 E5.
    Janssens S; de Armas HN; Roberts CJ; Van den Mooter G
    J Pharm Sci; 2008 Jun; 97(6):2110-20. PubMed ID: 17847067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Eudragit EPO and hydroxypropyl methylcellulose on drug release rate, supersaturation, precipitation outcome and redissolution rate of indomethacin amorphous solid dispersions.
    Xie T; Gao W; Taylor LS
    Int J Pharm; 2017 Oct; 531(1):313-323. PubMed ID: 28844901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissolution of Danazol Amorphous Solid Dispersions: Supersaturation and Phase Behavior as a Function of Drug Loading and Polymer Type.
    Jackson MJ; Kestur US; Hussain MA; Taylor LS
    Mol Pharm; 2016 Jan; 13(1):223-31. PubMed ID: 26618718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of induction methods for supersaturation: Amorphous dissolution versus solvent shift.
    Plum J; Bavnhøj CG; Eliasen JN; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2020 Jul; 152():35-43. PubMed ID: 32376371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase Behavior of Ritonavir Amorphous Solid Dispersions during Hydration and Dissolution.
    Purohit HS; Taylor LS
    Pharm Res; 2017 Dec; 34(12):2842-2861. PubMed ID: 28956218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.